Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06716580
NA

EQUAL: EGFR ctDNA QUantative Assessment for Lung Cancer Screening in Asian and Latinx Populations

Sponsor: Dana-Farber Cancer Institute

View on ClinicalTrials.gov

Summary

This research study is studying a new blood test to screen for Epidermal Growth Factor Receptor (EGFR) positive lung cancer in healthy individuals at risk for the disease and who cannot undergo regular lung cancer screening. The name of the test used in this research study is: -Circulating free DNA (cfDNA) Assay

Key Details

Gender

All

Age Range

40 Years - 80 Years

Study Type

INTERVENTIONAL

Enrollment

1000

Start Date

2025-04-01

Completion Date

2030-09-01

Last Updated

2025-12-10

Healthy Volunteers

Yes

Interventions

DEVICE

Circulating Tumor DNA (ctDNA) Assay

Screening investigational blood test to test for EGFR L858R and exon 19 deletions, which comprise 85-90% of total EGFR mutations. A positive or indeterminate investigational test will be followed up by CLIA verification of results. A positive or indeterminate CLIA result will be followed up by a lung CT scan. A positive CT scan will be followed up by referral for further evaluation. A negative CT scan will be followed up by a repeat scan in 12 months.

Locations (6)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Dana-Farber Cancer Institute

Boston, Massachusetts, United States

Massachusetts General Hospital

Boston, Massachusetts, United States

Dana-Farber Cancer Institute at Steward St. Elizabeth's

Brighton, Massachusetts, United States

Dana-Farber Cancer Instiute Merrimack Valley

Methuen, Massachusetts, United States

Dana-Farber Cancer Institute South Shore

South Weymouth, Massachusetts, United States